{'fraction_non_alphanumeric': 0.012665862484921592, 'fraction_numerical': 0.009650180940892641, 'mean_word_length': 5.9125, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Eudragit RL100 Based Moxifloxacin Hydrochloride and Ketorolac Tromethamine Combination Nanoparticulate System for Ocular Drug Delivery.

BACKGROUND
Bacterial conjunctivitis is a serious ocular infection if left untreated. It is caused by several species of bacteria like pseudomonas, staphylococcus and mycobacterium.


OBJECTIVE
The present investigation explores the development and characterization of moxifloxacin hydrochloride and ketorolac tromethamine combination loaded Eudragit RL 100 nanosuspension for ocular drug delivery in order to overcome the problems associated with conventional dosage forms.


METHODS
Nanosuspension prepared by nanoprecipitation technique showed successful entrapment of both water soluble drugs in polymer matrix indicated by their % entrapment efficiencies.


RESULTS
Formulations showed mean particle size <200nm with narrow size distribution and positive surface charge due to the presence of quaternary ammonium groups of Eudragit RL100. FTIR study revealed compatibility among the components while reduction in crystallinity of formulation was observed in PXRD study. Release of both the drugs was found to be sustained in nanosuspension as compared to commercial eyedrop. Ex vivo studies showed increased transcorneal permeation of drugs from nanosuspension where approximately 2.5-fold and 2-fold increase in the permeation was observed for moxifloxacin hydrochloride and ketorolac tromethamine, respectively. Formulation was stable at 4°C and room temperature.


CONCLUSION
Due to their sustained release, positive surface charge and higher transcorneal permeation, this will be a promising ocular drug delivery.